Recent developments highlight FDA alignment and support for OKYO Pharma's Urcosimod clinical trials, leadership changes, and capital raising activities.

• OKYO Pharma gained FDA alignment to advance Urcosimod, supporting clinical development progress [N1].
• The FDA supports advancement of the NEPTUNE clinical trial for Urcosimod, indicating regulatory engagement [N2].
• The company announced acceptance of Urcosimod Phase 2 study results for presentation at the ASCRS Annual Meeting, reflecting clinical progress [N6].
• FDA authorized compassionate use of Urcosimod 0.05% for neuropathic corneal pain, expanding access to the drug candidate [N7].
• Leadership transition occurred with CEO Gary Jacob moving to Chief Development Officer and Robert Dempsey appointed as CEO [N3].
• OKYO Pharma priced a $20 million share offering at $1.85 per share to raise capital for operations [N5].
• Shares gained after FDA endorsement of Phase 2b/3 trial design for Urcosimod, indicating positive market response to regulatory news [N8].

OKYO Pharma has advanced its lead drug candidate Urcosimod through clinical development with FDA alignment and support, including endorsement of Phase 2b/3 trial design and compassionate use authorization. The company has demonstrated progress by presenting Phase 2 study results at a prestigious ophthalmology meeting and has secured funding through equity offerings to support ongoing development. Leadership changes and insider share purchases indicate active management and insider confidence. The focused clinical development program and regulatory engagement provide a clear pathway for potential future commercialization in a niche therapeutic area.

OKYO Pharma operates without current product revenue and has reported significant net losses and negative cash flows from operations, with liquidity ratios indicating short-term constraints. The company depends on external financing, which may dilute existing shareholders and is subject to market conditions. Clinical development and regulatory approval processes carry inherent risks, including trial outcomes, patient enrollment, and regulatory decisions. Increased expenses related to clinical trials, regulatory filings, and infrastructure expansion may strain financial resources. The company faces typical risks of clinical-stage biopharmaceutical firms, including uncertainty in achieving successful commercialization and maintaining intellectual property protection.

OKYO Pharma's moat is primarily based on its proprietary clinical-stage drug candidate Urcosimod and its intellectual property portfolio. The company has secured regulatory interactions and FDA alignment supporting its clinical development pathway, which may provide a competitive advantage in the niche area of neuropathic corneal pain treatment. However, as a clinical-stage company without approved products or revenue, its moat is contingent on successful clinical development, regulatory approvals, and the ability to protect its intellectual property. The specialized focus on ophthalmic indications and the advancement of Urcosimod through clinical trials contribute to its differentiation, but the company faces typical risks of clinical-stage biopharmaceutical firms including regulatory, clinical, and financial uncertainties.

• Clinical Development Risk: The success of OKYO Pharma depends on the outcomes of clinical trials for Urcosimod, including patient enrollment, safety profile establishment, and regulatory approvals, which are inherently uncertain.
• Regulatory Risk: The company faces risks related to obtaining and maintaining marketing approvals from regulatory authorities, which can impact the timing and ability to commercialize product candidates.
• Financial and Liquidity Risk: OKYO Pharma has reported net losses and negative cash flows with limited liquidity ratios, indicating potential challenges in funding ongoing operations without additional financing.
• Operational Risk: Increasing expenses related to clinical development, regulatory compliance, infrastructure expansion, and personnel growth may strain resources and operational capacity.
• Market and Commercialization Risk: There is uncertainty regarding the company's ability to establish commercial manufacturing, sales, marketing, and distribution capabilities if product candidates receive approval.

• OKYO Pharma Ltd is a clinical-stage pharmaceutical company focused on developing product candidates, primarily Urcosimod, for treatment of neuropathic corneal pain and other indications.
• The company has not generated any revenue from product sales to date and does not expect to generate revenue in the near future.
• Research and development expenses are a significant part of the company's operating expenses, with $1.8 million spent in the year ended March 31, 2026, primarily on Urcosimod.
• General and administrative expenses increased to $6.7 million in the year ended March 31, 2026, driven by option charges, legal, recruitment, and public relations expenses.
• The company reported a net loss of $8.95 million for the year ended March 31, 2026, and an accumulated deficit of $152 million as of that date.
• Cash and cash equivalents were $4.6 million as of July 31, 2025, with a current ratio of 0.4 and cash ratio of 0.5, indicating liquidity constraints.
• OKYO Pharma has received FDA alignment and support for advancing its Urcosimod clinical trials, including endorsement of Phase 2b/3 trial design and compassionate use authorization for neuropathic corneal pain.
• The company announced acceptance of Urcosimod Phase 2 study results for presentation at a prestigious ophthalmology meeting (ASCRS).
• Leadership changes include the transition of CEO Gary Jacob to Chief Development Officer and appointment of Robert Dempsey as CEO.
• The company has raised capital through share offerings, including a $20 million share offering priced at $1.85 per share in February 2026.
• OKYO Pharma's clinical development program for Urcosimod includes the NEPTUNE clinical trial, which has FDA support for advancement.
• The company funds operations primarily through equity issuance, convertible loan notes, and has experienced net losses and negative cash flows from operations.
• The company expects expenses to increase as it advances clinical trials, regulatory filings, and prepares for potential commercialization, including building infrastructure and expanding personnel.
• The company operates with a focus on compliance with regulatory requirements and maintaining intellectual property rights.
• Recent insider share purchases by the Chief Scientific Officer indicate ongoing insider confidence.